



10-18-05

IP

Please type a plus sign (+) inside this box →

+

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/684,796
		Filing Date	October 14, 2003
		First Named Inventor	GARMAN, JONATHAN DAVID
		Group Art Unit	1644
		Examiner Name	Unassigned
Total Number of Pages in This Submission	5 + Refs.	Attorney Docket Number	VITA-019

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input checked="" type="checkbox"/> USPTO Form SB08A <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. 20 cited references 2. Return postcard
Remarks		



SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Signing Attorney/Agent (Reg. No.)	JAMES S. KEDDIE, PH.D. 48,920 BOZICEVIC, FIELD & FRANCIS, LLP
Signature	
Date	October 11, 2005

EXPRESS MAIL LABEL NO. EV 687 633 566 US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Express Mail No. EV 687 633 566 US

**INFORMATION
DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97**

Address to:
Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Attorney Docket	VITA-019
First Named Inventor	GARMAN, JONATHAN DAVID
Application Number	10/684,796
Confirmation No.	4233
Filing Date	October 14, 2003
Group Art Unit	1644
Examiner Name	Unassigned
Title: 'MODULATION OF SIGNAL TRANSDUCTION PATHWAYS'	

Sir:

Applicants hereby submit an Information Disclosure Statement along with attached form(s) PTO/SB/08. Copies of most listed publications are being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicants further request that the Examiner initial and return the attached form(s) PTO/SB/08 in accordance with MPEP §609.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in §1.56.

This statement qualifies under 37 C.F.R. §1.97, subsection (b) because:

- (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- (2) It is being filed within 3 months of entry of a national stage
-- OR --
- (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --

(4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

Copies of references listed on the attached Form PTO/SB/08 are enclosed herewith EXCEPT THAT:

In view of the voluminous nature of references, and the likelihood that these references are available to the Examiner in the file history of the parent application (Serial No. 60/418,042), copies are not enclosed herewith.

If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.


Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i)).

There are no listed references which are not in the English language.

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number VITA-019.


Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: October 11, 2005

By: 

James S. Keddie, Ph.D.
Registration No. 48,920

Bozicevic, Field & Francis, LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



OCT 11 2005

TO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/684,796
Filing Date	October 14, 2003
First Named Inventor	GARMAN, JONATHAN DAVID
Art Unit	1644
Examiner Name	4233

1

of

2

Attorney Docket Number VITA-019

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-5,994,506	11-30-1999	Soppet, et al.	
		US-6,406,871	06-18-2002	Pausch, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ – Number ⁴ – Kind Code ⁵ (if known)				
		WO 00/13161	03-09-2000	Mellander		
		WO 00/69897	11-23-2000	Lu		
		WO 00/69898	11-23-2000	Lu		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		AARTS, et al., "Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions," (2002) <i>Science</i> , 298:846-850	
		ANGLIN, et al., "Review Induction of prostate apoptosis by α_1 -adrenoceptor antagonists: mechanistic significance of the quinazoline component," (2002) <i>Prostate Cancer and Prostatic Diseases</i> , 5(2):88-95	
		DEBEIR, et al., "Protective effects of the α_1 -adrenoceptor antagonist, dexeparoxan, against degeneration of the basalocortical cholinergic system induced by cortical devascularization in the adult rat," (2002) <i>Neuroscience</i> , 115(1):41-53	
		DJAVAN, "Lower urinary tract systems/benign prostatic hyperplasia: fast control of the patient's quality of life," (2003) <i>Urology</i> , 62:6-14	
		GOWING, et al., "Alpha2 adrenergic agonists for the management of opioid withdrawal (Review)," (2003) <i>Cochrane Database Syst Rev</i> , (2):CD002024	
		GREGORINI, et al., "Effects of selective α_1 - and α_2 -adrenergic blockade on coronary flow reserve after coronary stenting," (2002) <i>Circulation</i> , 106:2901-2907	
		POOL, et al., "Clinical significance of α_1 -adrenoceptor selectivity in the management of benign prostatic hyperplasia," (2001) <i>International Urology and Nephrology</i> , 33:407-412	
		PUPO, et al., "Interaction of neuronal nitric oxide synthase with alpha ₁ -adrenergic receptor subtypes in transfected HEK-293 cells," (2002) <i>BMC Pharmacology</i> , 2:17	

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i></p>				<i>Complete if Known</i>			
				Application Number		10/684,796	
				Filing Date		October 14, 2003	
				First Named Inventor		GARMAN, JONATHAN DAVID	
				Art Unit		1644	
				Examiner Name		Unassigned	
Sheet	2	of	2	Attorney Docket Number	VITA-019		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ROEHRBORN, "Are all α -blockers created equal? An update," (2002) <i>Urology</i> 59:3-6	
		SAVOLA, et al., "Fipamezole (JP-1730) is a potent α_2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's Disease," (2003) <i>Movement Disorders</i> , 18(8):872-883	
		STEWART, et al., "Clinical and physiological effects of an acute α -1 adrenergic agonist and a β -1 adrenergic antagonist in chronic orthostatic intolerance," (2002) <i>Circulation</i> , 106:2946-2954	
		STONE, et al., "Emerging evidence for a central epinephrine-innervated α -adrenergic system that regulates behavioral activation and is impaired in depression," (2003) <i>Neuropsychopharmacology</i> , 28:1387-1399	
		TATTON, et al., "Hypothesis for a common basis for neuroprotection in glaucoma and alzheimer's disease: anti-apoptosis by alpha-2-adrenergic receptor activation," (2003) <i>Survey of Ophthalmology</i> , 48sup1:S25-S37	
		TEETERS, et al., "Systemic α_1 -adrenoceptor antagonist inhibits neointimal growth after balloon injury of rat carotid artery," (2003) <i>American Journal of Physiology (Heart and Circulation Physiology)</i> , 284:H385-H392	
		VELLIQUETTE, et al., "The role of I ₁ -imidazoline and α_2 -adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X," (2003) <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 306(2):646-657	
		WHEELER, et al., "Role of alpha-2 agonists in neuroprotection," (2003) <i>Survey of Ophthalmology</i> 48sup1:S47-S51	
		WILLEMS, et al., "Possible role of α -adrenoceptor subtypes in acute migraine therapy," (2003) <i>Cephalgia</i> , 23:245-257	
Examiner signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.